Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation
ReviewHumansOther animals
- Design
- Review
- Subjects
- Not applicable; this is a narrative review, not a single study
- Dose used in the study
- Not applicable; this is a narrative review, not a single study
- Duration
- Not applicable; this is a narrative review, not a single study
- What was measured
- How palmitoylethanolamide and ultramicronised PEA (umPEA) are thought to work, and what the evidence shows for neuroprotection, chronic pain and immune modulation
What the authors reported
The review describes PEA acting mainly through PPAR-alpha, with additional effects via CB1/CB2, GPR55 and TRPV1. Ultramicronised PEA has improved bioavailability, and in the preclinical and clinical studies cited it reduces neuroinflammation, stabilises mast cells and enhances endocannabinoid system activity, with what the authors describe as a well-established safety profile.
Limits of this study
A narrative review summarising other studies, not new data of its own; it does not independently verify the claims it summarises. The authors declare no conflicts of interest.
Source
PubMed 40563990 · doi:10.3390/biomedicines13061271
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.